Physician profile
William Pedro Jacks
NPI 1659353878
$11,943.69
in general payments reported to CMS, 2019-2025
49 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $611 · 2021: $1,865 · 2022: $1,743 · 2023: $1,901 · 2024: $2,208 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,536.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,501.52 | 2021-2025 | |
| Novo Nordisk INC | $1,198.51 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astellas Pharma US INC | $1,089.43 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $730.61 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $612.39 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.71 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $466.57 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $440.00 | 2022-2025 | |
| Lilly USA, LLC | $339.14 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Hologic Sales and Service, LLC | $195.12 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $166.06 | 2021-2025 | Verquvo |
| Dexcom, INC. | $148.35 | 2021-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $148.08 | 2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $146.77 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.